pah header
home
pah_people
Peptech Animal Health company information
suprelorin
ovuplant
news
general_links
contact_us

Ovuplant®
ovuplant sub menu
Ovuplant general information
ovuplant What is it
ovuplant advantages
ovuplant trial data

Advantages:
 

Safe:

Five year programme of safety testing in 10 countries including Australia, New Zealand, Canada and Germany

  • Tested in > 1000 mares for registration purposes
  • Minimal or no tissue reaction (short duration small oedemas - 1-3 days)
  • Pure, synthetic product - no viral contamination
  • Pregnancy data indicates no adverse reactions

Effects on Pregnancy Rates of Early Losses and Late Abortions (See figure below)
Studies and locations
Placebo (n)
Placebo Early Losses
Placebo Abort
Ocuplant® (n)
Ovuplant® Early Losses
Ovuplant® Abortions
Dose (USA)
20
3
0
20
0
 0
Clinical (USA/CAN)
85
6
0
86
2
0
Clinical (Germany)
 34 2 0 34 1 0
Clinical (Sweden)
 19 0 0 20 2 0
Clinical (USA/CAN)
 49 3 0 49 2 0
TOTAL
 207 14 0 209 7 0

Reliable:

Results of Ovuplant® experiments: Australia, Germany, Canada, Sweden and USA (1990-1992) (See figure below)
Treatment Mares (n) Treatment to Ovulation (hrs) Mares ovulating within 48 hrs (%)
Ovuplant® 531 45.6 91.1
Placebo 453 76.6 34.7
Intervals from Treatment to Ovulation (in hours)
Total (n) Placebo (n) Placebo (hrs) Ovuplant® (n) Ovuplant® (hrs)
All Mares 397 196 73.9 201 46.4
Non-Lactating Mares 111 56 81.8 55 47.8
Lactating Mares 168 83 68.2 85 45.3

Cost-Effective:

  • Less ultrasound/rectal examinations
  • Cross coverings eliminated
  • Post servicing ovulation checks are no longer required

No Refractiveness:

Deslorelin is a synthetic, much smaller molecule than hCG. The product is non-immunogenic thus no antibodies are developed. This can happen with use of hCG as it is a foreign material retrieved from urine of pregnant women. Repetitive dosing of hCG has been shown to result in antibody formation (Roser et al, 1979), "we do not recommend use of hCG in successive cycles" (McKinnon, 1996)

  • Multiple administration in the same breeding season reliably induces ovulation

Easy to Use:

  • Subcutaneous implant placed in the neck
  • Preloaded in a disposable syringe
  • No need for removal
  • Administered when dominant follicle is >30 mm diameter
  • Simple to administer >90% of treated mares ovulate within 36-48 hours
  • No antibody production
  • Repeated use does not diminish its effectiveness
  • Synthetic - no viral contamination
  • No deleterious effects on fertility of mares
  • No deleterious effects on embryonic or foal viability